X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (31728) 31728
Newspaper Article (4022) 4022
Newsletter (2192) 2192
Book Chapter (136) 136
Magazine Article (134) 134
Book / eBook (50) 50
Trade Publication Article (43) 43
Transcript (33) 33
Web Resource (21) 21
Dissertation (20) 20
Publication (10) 10
Book Review (7) 7
Conference Proceeding (7) 7
Government Document (4) 4
Reference (3) 3
Journal / eJournal (1) 1
Report (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
immunotherapy (32163) 32163
humans (21714) 21714
female (9293) 9293
cancer (9193) 9193
immunology (9126) 9126
male (9037) 9037
oncology (8907) 8907
animals (7083) 7083
middle aged (6436) 6436
adult (5993) 5993
care and treatment (5818) 5818
clinical trials (4776) 4776
tumors (4682) 4682
chemotherapy (4638) 4638
aged (4531) 4531
research (4374) 4374
treatment outcome (4339) 4339
patients (4338) 4338
health aspects (4235) 4235
immunotherapy - methods (4138) 4138
lymphocytes (3987) 3987
cancer therapies (3985) 3985
melanoma (3870) 3870
antigens (3635) 3635
metastasis (3481) 3481
transplantation (3340) 3340
therapy (3323) 3323
medical research (3070) 3070
t cells (3043) 3043
analysis (3024) 3024
drug therapy (2918) 2918
allergy (2915) 2915
immune system (2835) 2835
mice (2702) 2702
hematology (2517) 2517
dendritic cells (2494) 2494
surgery (2458) 2458
cytokines (2403) 2403
medicine & public health (2353) 2353
vaccines (2320) 2320
medicine, research & experimental (2299) 2299
review (2209) 2209
adolescent (2204) 2204
lymphocytes t (2153) 2153
proteins (2090) 2090
immunosuppression (2041) 2041
child (2040) 2040
antibodies, monoclonal - therapeutic use (2025) 2025
studies (2007) 2007
double-blind (1987) 1987
neoplasms - therapy (1941) 1941
risk factors (1894) 1894
cytotoxicity (1865) 1865
safety (1839) 1839
survival (1817) 1817
immunotherapy - adverse effects (1800) 1800
apoptosis (1795) 1795
pharmacology & pharmacy (1776) 1776
neoplasms - immunology (1770) 1770
antibodies (1737) 1737
ipilimumab (1729) 1729
t-cells (1729) 1729
expression (1721) 1721
children (1698) 1698
asthma (1693) 1693
monoclonal antibodies (1677) 1677
prognosis (1660) 1660
immune response (1623) 1623
medicine, experimental (1623) 1623
t-lymphocytes - immunology (1611) 1611
lung cancer (1607) 1607
antineoplastic agents - therapeutic use (1586) 1586
disease (1561) 1561
clinical trials as topic (1539) 1539
medicine (1510) 1510
medical prognosis (1508) 1508
efficacy (1468) 1468
retrospective studies (1443) 1443
young adult (1416) 1416
immunoglobulins (1414) 1414
inflammation (1413) 1413
nivolumab (1413) 1413
immunosuppressive agents - therapeutic use (1368) 1368
regulatory t-cells (1354) 1354
usage (1339) 1339
immune checkpoint (1315) 1315
allergies (1309) 1309
allergens (1308) 1308
vaccination (1304) 1304
combined modality therapy (1296) 1296
stem cells (1289) 1289
development and progression (1288) 1288
drug dosages (1287) 1287
leukemia (1262) 1262
aged, 80 and over (1254) 1254
biotechnology & applied microbiology (1245) 1245
metastatic melanoma (1242) 1242
biomarkers (1239) 1239
toxicity (1231) 1231
metastases (1228) 1228
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (37753) 37753
German (228) 228
French (217) 217
Japanese (127) 127
Chinese (85) 85
Spanish (70) 70
Russian (55) 55
Polish (33) 33
Italian (26) 26
Portuguese (23) 23
Korean (14) 14
Danish (11) 11
Czech (9) 9
Hungarian (9) 9
Dutch (8) 8
Turkish (6) 6
Norwegian (5) 5
Hebrew (4) 4
Romanian (4) 4
Bulgarian (3) 3
Slovenian (2) 2
Swedish (2) 2
Arabic (1) 1
Finnish (1) 1
Icelandic (1) 1
Lithuanian (1) 1
Serbian (1) 1
Ukrainian (1) 1
Urdu (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Critical care (London, England), ISSN 1364-8535, 2017, Volume 21, Issue 1, pp. 89 - 89
.... The majority of adverse events can be classified as mild or moderate, but severe and life-threatening complications requiring ICU admission also occur... 
Interdisciplinary management | Targeted therapy | Toxicity | Immunotherapy | Cancer | SAFETY | RISK | CHRONIC MYELOID-LEUKEMIA | TYROSINE KINASE INHIBITORS | THERAPY | BLINATUMOMAB | ARTERIAL OCCLUSIVE DISEASE | RECEPTOR T-CELLS | ADVERSE EVENTS | IPILIMUMAB | CRITICAL CARE MEDICINE | Immunotherapy - methods | Pyrazoles - therapeutic use | Drug-Related Side Effects and Adverse Reactions - complications | Humans | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Intensive Care Units - organization & administration | Immunotherapy - adverse effects | Neoplasms - drug therapy | Antibodies, Bispecific - therapeutic use | Antibodies, Bispecific - adverse effects | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Systemic Inflammatory Response Syndrome - etiology | Systemic Inflammatory Response Syndrome - complications | Drug-Related Side Effects and Adverse Reactions - physiopathology | Systemic Inflammatory Response Syndrome - drug therapy | Drug-Related Side Effects and Adverse Reactions - diagnosis | Cytokines - adverse effects | Pyrazoles - adverse effects | Cardiac arrhythmia | Disease | Leukemia | Colorectal cancer | Cytotoxicity | Kinases | Cancer therapies | Proteins | Neurotoxicity | Cell growth | Ischemia | Pharmaceutical industry | Vascular endothelial growth factor | Antigens | Immunoglobulins | Cytokines | Diarrhea | Breast cancer | Patients | Meta-analysis | Inflammatory bowel disease | Chemotherapy | Lymphomas | Tumors | Index Medicus
Journal Article
European journal of cancer (1990), ISSN 0959-8049, 2016, Volume 54, pp. 139 - 148
Journal Article
Blood, ISSN 1528-0020, 2012, Volume 119, Issue 20, pp. 4619 - 4624
Approximately 5-10% of diffuse large B-cell lymphomas (DLBCL) harbor a 8q24/MYC rearrangement (MYC+). We determined the prognostic significance of MYC... 
REARRANGEMENT | IMPACT | POOR-PROGNOSIS | T(14/18) | IN-SITU HYBRIDIZATION | CLASSIFICATION | HEMATOLOGY | EXPRESSION | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Podophyllotoxin - adverse effects | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Salvage Therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Dexamethasone - adverse effects | Male | Transplantation, Autologous | Cytarabine - adverse effects | Cisplatin - administration & dosage | Young Adult | Lymphoma, Large B-Cell, Diffuse - therapy | Melphalan - adverse effects | Immunotherapy | Treatment Failure | Podophyllotoxin - administration & dosage | Adult | Female | Chemotherapy, Adjuvant | Carmustine - adverse effects | Genes, myc - physiology | Dexamethasone - administration & dosage | Etoposide - adverse effects | Lymphoma, Large B-Cell, Diffuse - drug therapy | Ifosfamide - adverse effects | Rituximab | Etoposide - administration & dosage | Combined Modality Therapy | Cytarabine - administration & dosage | Lymphoma, Large B-Cell, Diffuse - mortality | Melphalan - administration & dosage | Ifosfamide - administration & dosage | Cisplatin - adverse effects | Aged | Hematopoietic Stem Cell Transplantation - methods | Antibodies, Monoclonal, Murine-Derived - adverse effects | Lymphoma, Large B-Cell, Diffuse - genetics | Carmustine - administration & dosage | Life Sciences | Biochemistry, Molecular Biology | Lymphoma, Large B-Cell, Diffuse | Podophyllotoxin | methods | Genes, myc | Cytarabine | genetics | administration & dosage | Melphalan | Antibodies, Monoclonal, Murine-Derived | Dexamethasone | drug therapy | Ifosfamide | Carmustine | therapy | Antineoplastic Combined Chemotherapy Protocols | Etoposide | physiology | Hematopoietic Stem Cell Transplantation | Cisplatin | adverse effects | mortality
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2012, Volume 30, Issue 21, pp. 2691 - 2697
.... We review the literature on managing the adverse effects and kinetics of tumor regression with ipilimumab and provide guidelines on their management... 
REGRESSION | METASTATIC MELANOMA | LYMPHOCYTE-ASSOCIATED ANTIGEN-4 | EFFICACY | ONCOLOGY | PHASE-II | MONOCLONAL-ANTIBODY | CTLA-4 | PATIENT | CANCER-IMMUNOTHERAPY | BLOCKADE | Stevens-Johnson Syndrome - immunology | Peripheral Nervous System Diseases - chemically induced | Skin Neoplasms - drug therapy | Humans | Ipilimumab | Antibodies, Monoclonal - adverse effects | Scleritis - chemically induced | Antineoplastic Agents - administration & dosage | Liver - immunology | Liver - drug effects | Antineoplastic Agents - adverse effects | Diarrhea - immunology | Pancreatitis - immunology | Scleritis - immunology | Mucous Membrane - drug effects | Colitis - immunology | Peripheral Nervous System Diseases - immunology | Antibodies, Monoclonal - immunology | Drug Eruptions - immunology | Skin - immunology | Melanoma - metabolism | Skin Neoplasms - pathology | Skin Neoplasms - immunology | Antineoplastic Agents - immunology | CTLA-4 Antigen - drug effects | Lymphatic Diseases - immunology | Antibodies, Monoclonal - pharmacokinetics | CTLA-4 Antigen - immunology | Pancreatitis - chemically induced | Melanoma - secondary | Chemical and Drug Induced Liver Injury - immunology | Pituitary Gland - immunology | Skin Neoplasms - metabolism | Lymphatic Diseases - chemically induced | Mucous Membrane - immunology | Antibodies, Monoclonal - administration & dosage | Melanoma - immunology | Uveitis - immunology | Melanoma - drug therapy | Uveitis - chemically induced | Pituitary Gland - drug effects | Skin - drug effects | Index Medicus
Journal Article
European journal of cancer (1990), ISSN 0959-8049, 2016, Volume 60, pp. 12 - 25
Journal Article
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2017, Volume 377, Issue 19, pp. 1813 - 1823
In patients with surgically resected melanoma, those with BRAF mutations who received 1 year of oral adjuvant therapy with dabrafenib and trametinib had a 53%... 
HIGH-RISK MELANOMA | SURVIVAL | MEDICINE, GENERAL & INTERNAL | INTERFERON-ALPHA-2B | PLACEBO | THERAPY | MEK INHIBITION | PHASE-III | DOUBLE-BLIND | HAZARD | IPILIMUMAB | Skin Neoplasms - drug therapy | Oximes - adverse effects | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Oximes - therapeutic use | Male | Adjuvants, Immunologic - adverse effects | Young Adult | Melanoma - genetics | Skin Neoplasms - mortality | Aged, 80 and over | Adult | Female | Imidazoles - therapeutic use | Adjuvants, Immunologic - therapeutic use | Skin Neoplasms - surgery | Double-Blind Method | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Pyrimidinones - therapeutic use | Neoplasm Recurrence, Local | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Skin Neoplasms - genetics | Adolescent | Survival Analysis | Aged | Pyridones - therapeutic use | Melanoma - surgery | Mutation | Neoplasm Staging | Pyridones - adverse effects | Melanoma - mortality | Usage | Relapse | Patient outcomes | Analysis | Melanoma | Adjuvant treatment | Outcome and process assessment (Health Care) | Reports | Drug therapy | Cancer | Diseases | Medical imaging | Oncology | Metastasis | FDA approval | Kinases | Cancer therapies | Survival | Skin cancer | Metastases | Medical prognosis | Immunotherapy | Drug dosages | Index Medicus | Abridged Index Medicus
Journal Article